Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis
Zi Chao Wu,Xin Yu Liu,Jia Yan Liu,Jing Shu Piao,Ming Guan Piao
DOI: https://doi.org/10.2147/IJN.S373430
IF: 7.033
2022-09-14
International Journal of Nanomedicine
Abstract:Zi Chao Wu, 1, 2, &ast Xin Yu Liu, 1, &ast Jia Yan Liu, 1 Jing Shu Piao, 1 Ming Guan Piao 1, 3 1 School of Pharmacy, Yanbian University, Yanji, 133002, People's Republic of China; 2 Research Institute, Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, 050035, People's Republic of China; 3 Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, 133002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ming Guan Piao; Jing Shu Piao, Email ; Aim: Liver fibrosis is mainly characterized by the formation of fibrous scars. Galactosylated chitosan (GC) has gained increasing attention as a liver-targeted drug carrier in recent years. The present study aimed to investigate the availability of betulinic acid-loaded GC nanoparticles (BA-GC-NPs) for liver protection. Covalently-conjugated galactose, recognized by asialoglycoprotein receptors exclusively expressed in hepatocytes, was employed to target the liver. Materials and Methods: Galactose was coupled to chitosan by chemical covalent binding. BA-GC-NPs were synthesized by wrapping BA into NPs via ion-crosslinking method. The potential advantage of BA-GC-NP as a liver-targeting agent in the treatment of liver fibrosis has been demonstrated in vivo and in vitro. Results: BA-GC-NPs with diameters < 200 nm were manufactured in a virtually spherical core-shell arrangement, and BA was released consistently and continuously for 96 h, as assessed by an in vitro release assay. According to the safety evaluation, BA-GC-NPs demonstrated good biocompatibility at the cellular level and did not generate any inflammatory reaction in mice. Importantly, BA-GC-NPs showed an inherent liver-targeting potential in the uptake behavioral studies in cells and bioimaging tests in vivo. Efficacy tests revealed that administering BA-GC-NPs in a mouse model of liver fibrosis reduced the degree of liver injury in mice. Conclusion: The findings showed that BA-GC-NPs form a safe and effective anti-hepatic fibrosis medication delivery strategy. Keywords: nanoparticles, lactobionic acid, chitosan, liver fibrosis, betulinic acid Liver fibrosis is a serious medical condition that develops as a result of chronic liver injury caused by various sources. 1,2 It is speculated to be a dynamic process marked by an excess of extracellular matrix components that lead to fibrous scarring. 3,4 The presence of a fibrous scar disrupts the architecture of the liver, disturbing the normal function of the liver. 5,6 Currently, anti-fibrosis therapy is a major concern for preventing the progression of liver disease. 7 One of the limiting factors is that candidate drugs are clinically ineffective or have limited antifibrotic effects in the liver and are frequently associated with toxicity in other organs. Therefore, developing effective anti-fibrosis therapy is critical. 8,9 Betulinic acid (BA) is a natural plant-derived pentacyclic triterpenoid acid that exists widely in nature and has several biological functions. 10,11 Typically, in a specific dosage range, BA is harmless to normal tissues. 12 Wan et al 13 demonstrated that BA reduces the increase in hydroxyproline and α-smooth muscle actin (α-SMA) in liver tissue mediated by thioacetamide (TAA) and plays a role in the prevention and treatment, showing great efficacy in liver fibrosis. Liu et al 14 showed that BA might be a viable novel medication for the treatment of liver fibrosis because it reduces the pathological damage related to liver fibrosis and can lower the serum platelet-derived growth factor and serum hydroxyproline levels by activating autophagy. Although BA has significant biological activity, and some disadvantages, such as poor water solubility and short in vivo half-life, hinder the clinical efficacy. 15,16 To overcome these drawbacks, some biodegradable polymer nanoparticles (NPs) of BA have been developed for cancer with excellent efficacy. 17,18 However, a nanoscale drug delivery carrier for BA has not yet been reported for anti-hepatic fibrosis therapy. Chitosan (CS) is a macromolecule straight chain polymer with unique physical and chemical properties and has become a research hotspot because of its biodegradability and biocompatibility. 19,20 Protonated amino groups and other active functional groups in CS participate in various bonding processes for chemical modification, endowing it with specific liver targeting function. 21,22 In recent years, galactose-modified CS has been d -Abstract Truncated-